;
Skip to main content
Home > SciBX > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Figure 1: Controlling insulin secretion via the adipose tissue-islet connection

    Targets & Mechanisms: Adipsin meets beta cells Figure 1. Controlling insulin secretion via the adipose tissue-islet connection. Lipids derived from ingested nutrients are metabolized to fatty acids that trigger an …

    Published on 8/7/2014
  • Adipsin meets beta cells

    A Harvard-led team has shown that adipsin increases insulin secretion by generating the complement peptide C3a. Its therapeutic potential might hinge on whether the effects persist with chronic dosing without triggering…

    Published on 8/7/2014
  • Neo enough in glioma

    A peptide containing a mutation in IDH1 could join the race for a cancer vaccine for glioma. The next question is whether the vaccine can jump-start an immune response in patients.

    Published on 7/31/2014
  • Taking a BET on hedgehog

    U.S. researchers show that BET bromodomain inhibition could open up a new therapeutic strategy for hedgehog-driven cancers that fail to respond to smoothened inhibitors.

    Published on 7/31/2014
  • Selecting CDK7

    A Harvard Medical School team has found a cyclin dependent kinase 7 inhibitor that covalently binds a cysteine outside the enzyme's kinase domain and suppresses leukemia in mice. Syros Pharmaceuticals has licensed the …

    Published on 7/24/2014
  • Hedgehog joins the resistance

    Hedgehog-mediated degradation of chemotherapeutics is a key resistance mechanism in AML, according to findings from Canadian researchers. Their next step is clinical testing of a chemotherapy-hedgehog antagonist …

    Published on 7/17/2014
  • New route for old cancer agents

    Researchers at the University of Wisconsin-Madison and Cellectar Biosciences have improved the safety of broad-spectrum cytotoxic drugs by engineering molecules that specifically target malignant cells. The key was …

    Published on 7/17/2014
  • Priming the PD pump

    No disease-modifying therapy has been developed to date for Parkinson's disease. Independent teams in Europe and the U.S. have now found that the dopamine transporter VMAT2 has a potentially causative role in the …

    Published on 7/10/2014
  • The pain of PIP2

    A UNC Chapel Hill team has found a way to block multiple pain receptors by antagonizing the lipid kinase PIP5K1C. Although a PIP5K1C inhibitor alleviates chronic pain in multiple mouse models, the lethality of PIP5K1C …

    Published on 7/10/2014
  • Table 1: A peek at PI3K inhibitors

    Targets & Mechanisms: PI3K inhibition: solid immunotherapy Table 1. A peek at PI3K inhibitors. According to a study in Nature by Ali et al., inhibition of phosphoinositide 3-kinase-d (PI3Kd) or the PI3K catalytic …

    Published on 6/26/2014
  • Managing meningitis

    SHX Vaccines is taking a different approach to vaccinating against meningitis -- preventing meningococci from binding to host cells in the first place. The company's academic collaborators have proof of concept for the …

    Published on 6/26/2014
  • PI3K inhibition: solid immunotherapy

    A new finding that links PI3Kdelta to T cell responses in a range of solid tumor types could expand use of PI3Kdelta inhibitors beyond the blood cancer setting and launch a new class of immunotherapies.

    Published on 6/26/2014
  • Collateral tumor damage

    Australian researchers have used T cells against antigens from a glioma cytomegalovirus rather than against tumor targets to attack brain cancer. The next step is to identify the best CMV epitopes for activating T cells…

    Published on 6/19/2014
  • CXCR2 antibodies for antitumor immunity

    An NCI team has identified a CXCR2-regulated pathway of tumor immune evasion that could account for some patients' resistance to checkpoint inhibitor-based therapies. The researchers are now planning to test anti-CXCR2 …

    Published on 6/19/2014
  • Figure 1: SMYD3 in cancer

    Targets & Mechanisms: Putting SMYD3 on the MAP Figure 1. SMYD3 in cancer. Mazur et al. have identified the role of SET and MYND domain containing 3 (SMYD3) in K-Ras (KRAS)-driven lung and pancreatic cancers. In …

    Published on 6/12/2014
  • Table 1: Selected MAPK pathway compounds in cancer

    Targets & Mechanisms: Putting SMYD3 on the MAP Table 1. Selected MAPK pathway compounds in cancer. Source: BCIQ: BioCentury Online Intelligence Company Compound Indication Target Status Amgen Inc. (NASDAQ:AMGN…

    Published on 6/12/2014
  • Box 1: Revisiting the pancreas

    Targets & Mechanisms: Stromal uncertainties in pancreatic cancer Box 1. Revisiting the pancreas. The insights into the nature of these aggressive, poorly differentiated pancreatic tumors suggest a niche for two …

    Published on 6/12/2014
  • Putting SMYD3 on the MAP

    Stanford and GlaxoSmithKline report that SMYD3 acts in the cytoplasm to regulate the MAPK pathway and not in the nucleus as previously thought. The discovery implies that inhibiting the enzyme can counter activating …

    Published on 6/12/2014
  • Stromal uncertainties in pancreatic cancer

    Despite the clear rationale for using hedgehog inhibitors in pancreatic cancer-they deplete the stroma to improve chemotherapy delivery-clinical results have been disappointing. New data suggest the large amounts of …

    Published on 6/12/2014
  • De-stressing glaucoma

    Glucocorticoids are standard care for a host of allergic and inflammatory eye conditions, but they can elevate intraocular pressure and result in secondary open-angle glaucoma. A chemical chaperone called sodium …

    Published on 6/5/2014
  • S100A9-clot not, bleed not

    U.S. researchers have shown that blocking S100 calcium binding protein A9 could prevent thrombosis without increasing the risk of bleeding. The findings may hand a new indication to at least two companies-InflammatoRx …

    Published on 5/29/2014
  • The DR is out

    Five years after a Genentech team proposed that DR6 was a member of a seemingly targetable pathway in Alzheimer's disease, the company and Rockefeller University have concluded that the proapoptotic pathway probably …

    Published on 5/15/2014
  • TLR4 on the surface of scleroderma

    BioLineRx's deal with the University of Colorado could give the biotech a disease-modifying therapy for cutaneous fibrosis in patients with diffuse systemic scleroderma. It remains unclear whether the university's TLR4 …

    Published on 5/8/2014
  • Figure 1: Bolstering cancer immunotherapy with IL-15

    Targets & Mechanisms: Leveling cancer with IL-15 Figure 1. Bolstering cancer immunotherapy with IL-15. (I) IL-15 is an immunostimulatory cytokine that typically is found pre-bound to the IL-15 receptor a-chain (IL-…

    Published on 4/24/2014
  • Leveling cancer with IL-15

    Findings that link high IL-15 levels in tumors with increased local T cell proliferation and favorable patient outcomes position the cytokine as a robust prognostic and complement ongoing efforts to develop IL-15 as a …

    Published on 4/24/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993